Mon, Jun 24, 4:04 PM (75 days ago)
Cell Source, Inc., a cell therapy company focused on immunotherapy, filed its annual report for the fiscal year ended December 31, 2023. The company is developing proprietary immune system management technology licensed from Yeda Research & Development Company Limited, targeting hematological malignancies and other severe medical conditions. Financial highlights include a limited operating history with ongoing operating losses and a need for significant additional financing. The company is not a well-known seasoned issuer and has not yet generated revenue. As of June 30, 2023, the market value of common stock held by non-affiliates was $23,624. Key risks include regulatory approval delays, clinical trial uncertainties, dependency on collaborative partners, and potential product liability. The strategic focus is on obtaining regulatory approvals and launching products initially in the U.S., Europe, and Asia. The company is conducting a Phase 1/2 clinical trial for its lead product candidate at MD Anderson Cancer Center.